Next Article in Journal
HIV mRNA Vaccines—Progress and Future Paths
Next Article in Special Issue
Construction and Immunogenicity Comparison of Three Virus-Like Particles Carrying Different Combinations of Structural Proteins of Avian Coronavirus Infectious Bronchitis Virus
Previous Article in Journal
Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization
Previous Article in Special Issue
Molecular Epidemiology of Group A Streptococcus Infections in The Gambia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 9
Issue 2
10.3390/vaccines9020133
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients

by
Claudia Sommerer
1,2,*,
Anita Schmitt
3,
Angela Hückelhoven-Krauss
3,
Thomas Giese
2,4,
Thomas Bruckner
5,
Lei Wang
3,
Paul Schnitzler
6,
Stefan Meuer
2,4,
Martin Zeier
1 and
Michael Schmitt
3
1
Department of Nephrology, University Hospital Heidelberg, University of Heidelberg, 69117 Heidelberg, Germany
2
German Center for Infection Research DZIF, 69117 Heidelberg, Germany
3
Department of Internal Medicine V, University of Heidelberg, 69117 Heidelberg, Germany
4
Institute of Immunology, University of Heidelberg, 69117 Heidelberg, Germany
5
Institute of Medical Biometry and Informatics, University of Heidelberg, 69117 Heidelberg, Germany
6
Department of Virology, University Hospital Heidelberg, University of Heidelberg, 69117 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Vaccines 2021, 9(2), 133; https://doi.org/10.3390/vaccines9020133
Submission received: 29 December 2020 / Revised: 23 January 2021 / Accepted: 4 February 2021 / Published: 6 February 2021
(This article belongs to the Special Issue Advances in Vaccine Development and Immunotherapies)
Browse Figure
Review Reports Versions Notes

Abstract

Introduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 peptide vaccination trial for seronegative end-stage renal disease patients waiting for kidney transplantation. Methods: The highly immunogenic nonamer peptide NLVPMVATV derived from CMV phosphoprotein 65(CMVpp65) in a water-in-oil emulsion (Montanide™) plus imiquimod (Aldara™) as an adjuvant was administered subcutaneously four times biweekly. Clinical course as well as immunological responses were monitored using IFN-γ ELISpot assays and flow cytometry for CMV-specific CD8+ T cells. Results: Peptide vaccination was well tolerated, and no drug-related serious adverse events were detected except for Grade I–II local skin reactions. Five of the 10 patients (50%) mounted any immune response (responders) and 40% of the patients presented CMV-specific CD8+ T cell responses elicited by these prophylactic vaccinations. No responders experienced CMV reactivation in the 18 months post-transplantation, while all non-responders reactivated. Conclusion: CMVpp65 peptide vaccination was safe, well tolerated, and clinically encouraging in seronegative end-stage renal disease patients waiting for kidney transplantation. Further studies with larger patient cohorts are planned.
Keywords: cytomegalovirus (CMV); CMV reactivation; phosphoprotein 65 (pp65) peptide vaccination; specific T cells; renal transplantation cytomegalovirus (CMV); CMV reactivation; phosphoprotein 65 (pp65) peptide vaccination; specific T cells; renal transplantation

Share and Cite

MDPI and ACS Style

Sommerer, C.; Schmitt, A.; Hückelhoven-Krauss, A.; Giese, T.; Bruckner, T.; Wang, L.; Schnitzler, P.; Meuer, S.; Zeier, M.; Schmitt, M. Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients. Vaccines 2021, 9, 133. https://doi.org/10.3390/vaccines9020133

AMA Style

Sommerer C, Schmitt A, Hückelhoven-Krauss A, Giese T, Bruckner T, Wang L, Schnitzler P, Meuer S, Zeier M, Schmitt M. Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients. Vaccines. 2021; 9(2):133. https://doi.org/10.3390/vaccines9020133

Chicago/Turabian Style

Sommerer, Claudia, Anita Schmitt, Angela Hückelhoven-Krauss, Thomas Giese, Thomas Bruckner, Lei Wang, Paul Schnitzler, Stefan Meuer, Martin Zeier, and Michael Schmitt. 2021. "Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients" Vaccines 9, no. 2: 133. https://doi.org/10.3390/vaccines9020133

APA Style

Sommerer, C., Schmitt, A., Hückelhoven-Krauss, A., Giese, T., Bruckner, T., Wang, L., Schnitzler, P., Meuer, S., Zeier, M., & Schmitt, M. (2021). Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients. Vaccines, 9(2), 133. https://doi.org/10.3390/vaccines9020133

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop